Podcasts about medulloblastoma

After Matt and Breanna's son 10 1/2 year old son Landon passed away from Medulloblastoma in December of 2022, Matt took up running as a way to cope with the grief from his beloved son's passing. In March of this year, Matt's running took him to Lake Folsom in Auburn California where he lives and he began a 140 mile run that honored the memory of Landon and honored 105 other Pediatric Cancer Warriors, some of whom are fighters. some of whom are survivors, and some of whom have passed away. This amazing accomplished was also captured on a 45 minute film which was put together by his "crew" of helpers who helped Matt every step of the way. 

Professor Nick Gottardo walks us through medulloblastomas - a comprehensive master class for clinicians and researchers.  Expect to learn about early signs and symptoms, diagnosis, treatment and prognosis. Dr Nick breaks this down beautifully.What was really clear throughout our discussion was that collaboration is key. Given the incidence of medulloblastomas and the specific subtypes that fall within this category, it would not be possible to develop effective treatments that minimise detrimental side effects without coming together with centres across the world.This episode is truly special so if you want to know the current state of the evidence when it comes to treating medulloblastomas - this is a must listen episode.

Side Effects and After Effects from any Pediatric Cancer battle can be very difficult, especially when there are so many side effects that are concerning after being diagnosed with Pediatric Brain Cancer. That is certainly the case as we just heard from Stacie Eirich in talking about her daughter Sadie who has had more than a few difficult obstacles to overcome. The hope is that she will find the right people and programs to help Sadie through her toughest times. 

After taking a swimming lesson in late July of 2022 in very hot conditions, 4 year old Aaron Kline showed concerning symptoms which led his mother Shana to take him to see his pediatrician. A few days later, Aaron was diagnosed with the Pediatric Brain Cancer Medulloblastoma. 7 months later, Aaron completed his treatment at Children's Hospital of Philadelphia and is currently feeling and doing well as a 6 year old first grade student. 

Hopefully for the 1ST and LAST time, I spoke with a mom and dad who had what I am calling a misfortune on Steroids when Tanya and Luke Palmowski's son Tyler was diagnosed with Medulloblastoma when he was 8 years old in 2015, was able to ring the bell at Stollery Children's Hospital in Edmonton, Albert 1 year later in 2016, and then just as Covid was hitting in March of 2020 was diagnosed with DIPG. Tyler passed away on November 24th of 2020 .

When Jamie Moore's 6 year old son Mason was experiencing headaches, having vomiting episodes, and having little energy, she and her husband were frustrated at first by the response they were receiving from doctors who did not recognize that what was happening to Mason was a "head issue". Mason was finally diagnosed with Anaplastic Large Cell Medulloblastoma on February 20th of 2023, had much of his treatment at St. Jude Childrens Research Hospital in Memphis, but for the most part the difficult treatment that he underwent did not help and he passed away on November 6th of 2023, just 10 months after his diagnosis. 

Sadie Eirich's left eye seemed out of position in the early fall of 2022 and eventually led to her diagnosis in October of that year of the Pediatric Brain Cancer Medulloblastoma, which was located in the pineal region of her brain. Sadie was 14 years old at the time and her treatment initially took her to a children's hospital in Jefferson Louisiana where she had 5 surgeries, followed by 9 months of treatment at St. Jude Children's Research Hospital from December of 2022 through September of 2023. Sadie was found to have No Evidence of Disease in September of 2023 and that situation continues to be the case nearly a year later. 

BEYOND A DIAGNOSIS ( A JOURNEY THROUGH CANCER) by Grace BoykinA memoir of her son Weslee Sheaffer. His birth, head banging, and having to drive him around the neighborhood for him to sleep. His many creative talents. Travel to Japan as Rotary exchange student and stayed in many homes in south and Northern Japan. He loved to travel! Cancer diagnosis of Medulloblastoma brain cancer, chemotherapy, and radiation treatment at Shands Hospital in Gainesville, Florida. Later he had a Meningioma Brain Tumor, His last was a glio-blastoma brain tumor with tentacles which is very rare to have 3 different types of brain cancer. His Celebration of Life as he died at age 32. Author Grace Boykin a native of Mobile, Alabama, Clearwater, Florida. Received B.A. degree in Social Science and Secondary Education from Flagler College in St. Augustine, Florida. Studied Art in Europe with Spring Hill College, Mobile, Alabama. Debut in Mobile and member of the Mardi Gras Court. Employed at Walt Disney World in Orlando, Florida. Taught Geography at Dunedin Junior High School and History in several schools throughout Melbourne, Florida. Tutored Braille and worked with the Blind at the Florida School of Deaf and Blind in St. Augustine, Fl. Taught and created a Mass Media Curriculum for High School students and Directed the High school play “To Serve a Higher King”, in Palm Bay, Florida.Has published works of Poetry, Fiction books The Southern Hunt, and Deaf, Blind, and Tragedy. Autobiography of Grace Browder Boykin, A Turbulent Life ? ? ?, South Of The Hill, memoir about the Political Years 1930's to 1960's of Frank W. Boykin as a U.S, Congressman for twenty-eight years and his having over 20 jobs during his lifetime., Beyond A Diagnosis, (A Journey Through Cancer) memoir of son Weslee Sheaffer. Babies Swimming Class. Grace Boykin is resident of Milton, Florida after traveling and driving all the states on backroads when possible. Visited 25 national parks and 25 countries. Her passions writing novels and carrying a camera in hand to make the next great movie.https://www.amazon.com/Books-Grace-Boykin/s?rh=n%3A283155%2Cp_27%3AGrace+Boykin  https://www.urlinkpublishing.com/http://www.bluefunkbroadcasting.com/root/twia/8824urlgb.mp3

Workup and management of Medulloblastoma in Radiation Oncology featuring guest Dr Steven Montalvo

Abby Wagle and Ella Bresee met in 2019 when they played competitive basketball against each other. They quickly became best friends and then in 2021, Ella was diagnosed with the Pediatric Brain Cancer Medulloblastoma. Abby is now a sophomore in high school and will talk about the close friendship that she and Ella had, and how difficult it was when Ella passed away in September of 2022. Abby will talk about the many ways that she has honored her friend since then and will continue to honor her in the years to come. 

It took a confirmation from St. Jude Children's Research Hospital to finally confirm that 6 year old Mia Falvey had Medulloblastoma after waiting for an official diagnosis for more than 30 days. Since the summer of 2022 Mia has been under treatment for this most common form of Pediatric Brain cancer and is waiting for an upcoming MRI which will tell the doctors what her next treatment protocol will look like. 

Sophia Takla's 8 year old cousin Tristan passed away from Medulloblastoma 15 years ago when Sophia was 8 years old, as was Tristan. Sophia will talk about that period of time and what she has been doing as a Pediatric Cancer advocate since his Tristan's passing and will continue to do for many years to come.  Sophia will also discuss her being crowned Miss Oregon in June of 2022 and her top 10 finish in the Miss America Pageant in 2023.  Sophia has accomplished so much in her life already and at 23 years old, has an incredibly promising future ahead . 

After being diagnosed with Medulloblastoma in March of 2021, Breanna and Matt Meo's 8 year old son Landon was admitted to St. Jude Children's Research Hospital to begin a clinical trial which was working well until Landon relapsed in March of 2022. Breanna and Matt will talk about the difficult treatment that Landon went through as well as some good times, especially in the first few months of 2022 when he was able to attend 3 Sacramento Kings basketball games, meet the players from that team, and meet Lebron James on April 7th, 8 months before his December 17th 2022 passing. 

On August 22nd of this year, exactly 8 weeks before today's podcast is being published, 7 year old Ashton Hawkins was diagnosed with the Pediatric Brain Cancer Medulloblastoma. On today's podcast, Ashton's mom Amanda will talk about what Ashton has been through over the past 8 weeks and what challenges that she faces as her treatment protocol is still in its early stages. 

Explore the benefits of zinc ointments, natural sources of vitamin A, top supplements for a healthy pregnancy and the potential factors contributing to the development of medulloblastomas! Tune in to hear: Healing the gut of a 1 year old (1:38) Essential supplements for a healthy pregnancy (4:04) An important vitamin you need during pregnancy (7:00) Understanding the root causes of warts (11:29) Medulloblastomas: what you should know (16:06)  Head to www.paulabenedi.com/episode111 for the show notes. Join my newsletter: www.synergised.info/newsletter Follow me on Instagram: @synergiseduk . P.S. This podcast and website represents the opinions of Paula Benedi. The content here should not be taken as medical advice and is for informational purposes only, and is not intended to diagnose, treat, cure or prevent any disease. Please consult your healthcare professional for any medical questions.

In questo episodio parleremo di medulloblastoma. Con l'aiuto degli specialisti dell'Ospedale Pediatrico Bambino Gesù, scopriremo come si manifesta, come si fa la diagnosi e come si cura. Episodio registrato martedì 6 giugno 2023.

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

Paul A. Northcott, Ph.D., St. Jude Children's Research Hospital, shares his work in multi-omic bulk and single-cell approaches to decipher molecular landscapes and developmental origins of medulloblastoma. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 38889]

In this episode, we review the high-yield topic of Medulloblastoma⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Neurology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

A new research perspective was published in Oncotarget's Volume 14 on February 7, 2023, entitled, “WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?” Novel biological insights have established that medulloblastoma is a heterogenous disease comprising four broad molecular subgroups - WNT, SHH, Group 3, and Group 4 respectively, resulting in the incorporation of molecular/genetic information in 5th edition of WHO classification and contemporary risk-stratification. Concerns regarding therapy-related late toxicity in long-term survivors have led to systematic attempts at treatment de-intensification in good-risk medulloblastoma. Given the excellent survival (>90%) of WNT-pathway medulloblastoma, prospective clinical trials have focused on optimization of therapy to balance survival versus quality of survival. The currently accepted definition of low-risk WNT-pathway medulloblastoma includes children

For our last episode of season five, Chris and Christy hosted Cory and Lix Mixdorf. The Mixdorf family has five children - Miles (age 14), Madelyn (age 12), Mason (age 11, Meyer (age 6), and Monty (age 5). Their cancer journey began when Myer was diagnosed with Medulloblastoma at four. From the beginning of the journey, they decided they didn't want this diagnosis to negatively impact their family and marriage. They chose to prioritize time together as a family and a married couple, no matter the circumstance. During the journey, they experienced an incredible community and many blessings. In closing, Cory and Liz shared some personal advice about walking the kids through trauma, not hiding their emotions, and accepting help when offered. Last but not least, they encourage families not to waste the story God is writing in your life. As we end season five, we have to take a moment to say "thank you." Thank you for listening each week. Thank you for sharing the podcast with friends and family. We will return for season six on February 7, 2023. In the meantime, please share your feedback on the Lighthouse Podcast with us: https://www.surveymonkey.com/r/ZF6LWV9 Follow Lighthouse on Social Media: Facebook: https://www.facebook.com/lighthousefamilyretreat Instagram: http://instagram.com/lighthousefr

The Pediatric Brain Cancer Medullomayoblastoma is not the same cancer as the much more common Medulloblastoma. On today's podcast Michael Pruitt will talk about his son Rylan who was diagnosed with this cancer when he was 5 years old in the spring of 2021, and passed away from it at the age of 6, on March 10th of this year. Before Rylan's diagnosis, only 51 cases of this cancer had been diagnosed with only 1 known survivor. Michael will also talk about the Rylan Strong Network that he founded, which has a major component of trying to enact legislation that will make certain that insurance companies and the particular hospital that a child is being treated at will pay for treatment, even if an insurance contract has not been signed. 

A new editorial paper was published in Oncotarget on September 8, 2022, by researchers Jingwen Zhu, Joseph N. Miller and John D. Schuetz from St. Jude Children's Research Hospital in Memphis, Tennessee, entitled, “An ABC transporter as a potential target against SHH-Medulloblastoma: From Benchtop to Bedside.” Medulloblastoma (MB) is a common malignant pediatric brain tumor divided into four main subgroups (WNT, SHH, Group 3 and 4). The most prevalent MB in children

 Olivia was diagnosed with a medulloblastoma brain tumor, the size of a small egg, in the lower back part of her brain, close to the brain stem in February 2016. Her parents had noticed she was vomiting and had some minor imbalance while walking. Olivia had six months of chemotherapy that started in March 2016. During her treatment, she had a Broviac port, several blood transfusions, a lumbar puncture and bone marrow scan, and a stem cell treatment plan. She had five different chemotherapy medications during her 6-month treatment. Her treatment endedSeptember 2016, although she does have her regular brain and spine scans every six months. Her doctors are Dr. Susan Chi and Dr. Michelle Lee. She also had two surgeries in 2020 after finding a vascular lesion (small bleeding blood vessel) in the front left part of Olivia's brain. Olivia is going into the third grade. She plays soccer, does gymnastics, loves doing Ninja, and takes dance. Her family is grateful to Dana-Farber for the degree of patient and family care they provide. They feel no details are overlooked or taken for granted. They say, “Dana-Farber makes you feel as though you are the most important person thereand you become part of a group that you have a connection with forever.” Andrea ran the Boston Marathon in 2016 during Olivia's treatment and Jason runs an "Olivia Strong" night every season at a Bristol Community College soccer game, where he is a coach, to raise money for the Jimmy Fund.

After being diagnosed with the pediatric brain cancer Medulloblastoma in 2004, Elizabeth Allen was able to survive her battle and move on to where she is now a graduate student at Tufts University, where she is studying nutrition, epidemiology, data science, and public health. Elizabeth will discuss the fact that of the many important facets of Pediatric Cancer and how they affect these kids, the subject of Nutrition is not prioritized and is not really talked about with any regularity. 

Jaclyn Murphy was diagnosed with Medulloblastoma when she was 9 years old. During her treatment, the Women's Lacrosse Team from Northwestern University found out about what Jaclyn was going through, and "Adopted" her as a team member. This act of kindness proved to be a special one for both Jaclyn and Northwestern, so much so that Jaclyn's father Denis and the Murphy family started the Friends Of Jaclyn Foundation. The central theme of this Foundation centers around its Adopt A Child Program, in which colleges and high schools around the country "Adopt" a Pediatric Cancer patient and make them a team member. This foundation was started in 2005 and is nearing 1000 patients that have been adopted with many more to join them in the future.Jaclyn is now 27 years old and is able to live a life of good health as she and her dad give so much back to kids who need it the most.

Medulloblastomas are the most common malignant brain tumour in children. They arise from embryonal neuroepithelial cells and are usually located in the cerebellum, which can cause cerebellar signs. Due to its location, the tumour can also compress the 4th ventricle, causing hydrocephalus. Definitive diagnosis is based on histology from surgical resection of the tumour, after which point children will also undergo radiotherapy and chemotherapy.  Follow us on Instagram @yourekiddingrightdoctors Our email is yourekiddingrightpod@gmail.com Make sure you hit SUBSCRIBE/FOLLOW so you don't miss any episodes and RATE to help other people find us! (This isn't individual medical advice, please use your own clinical judgement and local guidelines when caring for your patients)

After a 15 month battle with Medulloblastoma which began in July of 2006 and sadly ended in October of 2007, 5 year old Mason Leach lived a very short and very meaningful life. Mason's mother Danielle will detail Mason's battle and will talk about what she has done since that time to fight for all of these kids who have suffered from both Pediatric Brain Cancer and other cancers that kids have unfortunately been diagnosed with.Danielle will talk about her current position as the Director of Advocacy and Government Relations at the National Brain Tumor Society, and will discuss many of the advancements in the Pediatric Cancer fight that she has been involved with. 

Patti and Al Gustafson will talk about their son Michael, who passed away after a 5 year battle  with the pediatric brain cancer Medulloblastoma, During the late stages of his disease, Michael told his mom that he willing to give up his life "so that he could see if I can find a cure for cancer"  I will  also speak with Dr. Angela Waanders , who will talk about the importance of post mortem brain tissue donations, which could be a game changer in the future for pediatric brain cancer patients and their families.                                                                                                                                                                                 Advocating for these tissue donations is a major part of the Swifty Foundation which Michael was the inspiration behind, and which the Gustafson family run today as they are doing what they can to fight for these kids who receive such a difficult diagnosis. 

TW: cancer, mention of child death OH HEY! This is a decently special episode- it is actually the first one I ever recorded and the only one I recorded IN person. It was spur of the moment so the audio is a little off, but most of it is solid and of course, the content is important! PEDIATRIC BRAIN CANCER YO! Medulloblastoma! There are lots of organizations Hannah and I touch on, listed below! https://childrenwithhairloss.us/about-children-with-hair-loss/ https://fleeceandthankyou.org/ https://www.wishuponateen.org/ https://www.gktw.org/ and those stats- https://www.cancer.net/cancer-types/medulloblastoma-childhood

After an early childhood which included modeling and soccer, Cole Eicher was diagnosed with the Pediatric Brain Cancer Medulloblastoma when he was a 12 year old 6th grader.  As he entered the hospital , Cole noticed that there were many younger patients that were fighting their own cancer battles. He instinctively knew that this was not right and that he wanted to be a voice for these kids. So began the amazing advocacy work for so many children that Cole started  as a 12 year old while a patient himself,  and that this pediatric brain cancer survivor continues today. Cole will talk about setting up a meeting with American Cancer Society CEO Gary Reedy and  asked him to support the ideas that he had to help these children, including expanding the Relay For Life program . After Cole heard the word YES to his ideas , the Gold Together Non profit that he and his mom Laura started was well on its way.

Just 1 day after her son Jacob passed away from Medulloblastoma in 2009, Nancy Goodman started the Non Profit KIDS V CANCER.  Nancy will discuss this non profit, whose objective it is to find new methods and medicines to help in the fight against Pediatric Cancer. Nancy is one of the leading advocates on Capitol Hill for these kids, and her advocacy has produced a number of initiatives along with legislation that has produced successful results and promises to produce even more successful results as time goes on.

Tamara Miles lives in Sydney Australia with her husband and 4 sons. Her son Bryson is now 8 years old and 5 years past his diagnosis of Medulloblastoma, and her son Ryder who is 3 1/2  has endured 18 brain surgeries, none of which had anything to do with Pediatric Cancer. Tamara will talk about what has been a very difficult journey for Bryson and Ryder, plus the emotional strain that has affected both her and her husband Grant. Tamara will also talk about the problems that the hospitals in Sydney and other places in Australia face , as the government cannot afford to give these hospitals the money that they need to do as much as they can for the cause of Pediatric Cancer. 

Ricardo Garcia's son Richi was diagnosed with high risk Medulloblastoma when he was 6 years old in 2011 and living in Spain. The Garcia family moved to Brookline, Ma. after the diagnosis and now 10 years later, after going through treatment at Boston Children's Hospital and Dana Farber, Richi is doing well and leading a good life. Ricardo will talk about Richi's cancer battle, the Richi Childhood Cancer Foundation that he started in 2013, and the Biotech company Onceoheroes Biosciences that he cofounded a few years ago, which is is 100 percent focused on developing new drugs that will help pediatric cancer patients in future years. 

Tatum Fettig will talk about her daughter Teagan and her battle with Medulloblastoma, which she was diagnosed with just after her 2nd birthday in December of 2016. Now 4  1/2 years later Teagen is doing well and is about to enter 1st grade .Tatum will also discuss the first non profit nationwide APP that she designed, which allows parents of pediatric cancer patients to communicate with one another. This APP has only been available since September of 2020 and promises to allow parents to take advantage of a whole new level of communication, as they meet their fellow peers who are going through the same or similar issues that they are experiencing themselves. 

Carson Leslie was diagnosed with Medulloblastoma at the age of 14 in 2006 and passed away from this Pediatric Brain Cancer in January of 2010. Carson wrote a book entitled CARRY ME which was published just 6 days before his passing, in the hope that his words would comfort other Pediatric Cancer patients who would inevitably suffer from some form of cancer.His mother Annette will talk about Carson's life, and the Carson Leslie Foundation which is helping to make great strides in many aspects of Medulloblastoma. Having the support of Texas Congressman Mike McCaul, the Cancer Prevention and Research Institute of Texas (CPRIT) which spends 12 percent of it's money on Pediatric Cancer while the average public money spent on this is only 4 percent, and the Jordan Spieth Foundation,  Annette is the engine that is making certain that there will be easier treatments, and easier paths towards a cure for these children and adolescents who have to endure such a difficult disease. 

When Cole Eicher was 12 years old he was diagnosed with Medulloblastoma, which is the most common form of Pediatric Brain Cancer. After an intense 9 month treatment, Cole recovered from this disease. He has spent the past 7 years advocating for children who have experienced all forms of Pediatric Cancer.At the age of 12 Cole decided that he wanted to be a voice for children and families facing childhood cancer. As a volunteer for the American Cancer Society he wanted to see a childhood cancer team at Relay For Life events nationwide. Cole knew that it would provide a way for children to be empowered and supported in their community. After a few years of testing, Gold Together became a national program with the American Cancer Society in November of 2018. His mother Laura will talk about Cole's mission to create more ways for people to volunteer and support courageous kids in their community.

Medulloblastoma

In this week's episode, Dr. David Bakhshinyan joins us to discuss his path through graduate studies and postdoctoral training in industry. Dr. Bakhshinyan defended his Ph.D. in Biochemistry at McMaster University, which explored the development of murine models to study tumor recurrence in Pediatric Medulloblastoma. We also discuss tips on choosing a laboratory, and how he plans to bridge academia, industry, and the clinic.  Twitter @immunoNbeyond & Insta @immunologyandbeyond

Honestly, I’m not quite sure how to give my next guest Jen Burke a proper introduction. Jen is the President and founder of Saras Smiles. Her angel daughter Sara courageously underwent treatments for Medulloblastoma (a brain tumor) at the age of four. Heartbreakingly, she gained her wings less than a year after diagnosis but her memory still provides thousands of children smiles daily! It was an honor and a privilege to have some time to speak with Jen. I loved hearing about Sara, her interests and the special memories they share as mother and daughter. I’m truly in awe of Jen, what she’s created with Sara Smiles and what she provides for families like mine in memory of her daughter. Jen’s goal is to give kids fighting cancer as many smiles as possible and know they are not alone. My son, Ollie was a recipient of one of Sara Smiles Kits and we’re still exploring it! Stay tuned to learn how you can request one for your child too! Links: https://saras-smiles.org/ https://saras-smiles.org/kits/ --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/allmammacaretime/message Support this podcast: https://anchor.fm/allmammacaretime/support

On this episode, second-year occupational therapy students Bailey Diprima, Serena Khiantani, and Pam Ponce talk about the outcome of their work in a course in OT school on evidence-based practice. Their study looked at the outcome of medical interventions used with children ages 4-18 for treatment of medulloblastoma, a malignant (cancerous) type of brain tumor that originates in the cerebellum. Their work on this project can be accessed via the following link: https://dc.uthsc.edu/mot2/6/ Bailey, Serena, and Pam are students in the Master's degree OT program at the University of Tennessee Health Science Center in Memphis, TN.

On this episode, second-year occupational therapy students Bailey Diprima, Serena Khiantani, and Pam Ponce talk about the outcome of their work in a course in OT school on evidence-based practice. Their study looked at the outcome of medical interventions used with children ages 4-18 for treatment of medulloblastoma, a malignant (cancerous) type of brain tumor that originates in the cerebellum. Their work on this project can be accessed via the following link: https://dc.uthsc.edu/mot2/6/ Bailey, Serena, and Pam are students in the Master's degree OT program at the University of Tennessee Health Science Center in Memphis, TN.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.04.30.068726v1?rss=1 Authors: Hwang, D., Dismuke, T., Tikunov, A., Rosen, E., Kagel, J., Ramsey, J., Lim, C., Zamboni, W., Kabanov, A., Gershon, T. R., Sokolsky-Papkov, M. Abstract: We report a novel, nanoparticle formulation of the SHH pathway inhibitor vismodegib that improves efficacy for medulloblastoma treatment while reducing toxicity. Systemic therapies for brain tumors are complicated by restricted blood-brain barrier (BBB) permeability and dose-limiting extraneural toxicity, therefore improved delivery approached are needed. Here we show how a nanoparticle delivery system addresses these obstacles, bringing new efficacy to previously ineffective therapy. Vismodegib has been a promising agent for patients with SHH-subgroup medulloblastoma and is FDA-approved for basal cell carcinoma. However, vismodegib has limited benefit for patients with SHH-driven medulloblastoma, due to off-target toxicities and the development of resistance during therapy. We encapsulated vismodegib in polyoxazoline block copolymer micelles (POx-vismo). We then evaluated POx-vismo using transgenic mice engineered to develop endogenous medulloblastomas, testing the novel agent in a preclinical model with native vasculature and tumor microenvironment. POx-vismo showed improved CNS pharmacokinetics and reduced systemic and bone toxicity. Mechanistic studies show that POx nanoparticles did not enter the CNS, but rather acted within the vascular compartment to improve drug delivery by decreasing drug binding to serum proteins and reducing the volume of distribution. POx-vismo demonstrated improved efficacy, extending the survival of medulloblastoma-bearing mice. Our results show the potential for a simple, non-targeted nanoparticle formulation to improve systemic brain tumor therapy, and specifically to enhance vismodegib therapy for SHH-driven cancers. Copy rights belong to original authors. Visit the link for more info

Joshua Ervasti, otherwise known as a super uncle. Listen today as Josh tells the story of one courageous little girl battling brain cancer and the sport that spiked a movement. Maddie Cunningham had Medulloblastoma at the age of three. This Horrible type of brain cancer attacks the cerebellum creating a very difficult life of cognitive loss and fine motor skills as well as balance. Through a loving family and a super uncle, they created Maddie Cunningham's classic volleyball Challenge to bring awareness and funds to help all children suffering from medulloblastoma. Maddie has been in remission for some time and is 17! To find out more and to contact Josh, please visit: http://www.maddysclassicvolleyball.com/ Facebook: http://www.facebook.com/MaddysClassicVolleyball Jervasti0824@gmail.com

Sara Stamp is Sara Stamp the author of a newly released book called The Other F-Word: When Faith Fills the Gap. Sara is also the Executive Director of Layla’s Legacy Foundation, an organization created to raise money for innovative pediatric brain cancer research while also bringing hope and help to families impacted by the disease. Sara founded Laya’s Legacy with her husband Bryan after losing their 5-year-old daughter, Layla, to Medulloblastoma, which is the most common form of pediatric brain cancer. https://sarastamp.com/http://laylaslegacy.org/https://womensnpa.org/

Cancer has become one of the most dangerous diseases of the aging population of industrialized countries. Finding tools to fight cancer is hard, because Cancer presents itself as highly heterogeneous, with over 100 types of cancers described. Not only does Cancer affect aged humans, it has been observed in children in the form of e.g. Medulloblastoma. In the third episode of Active Motif's Epigenetics Podcast, our host Dr. Stefan Dillinger sits down with Dr. David Jones, group leader at the German Cancer Research Center in Heidelberg, to talk about his research on Medulloblastoma and also the emerging role of epigenetic factors in Cancer. References for this episode Alioto, Ivo Buchhalter, … Ivo G. Gut. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nature Communications. 2015 Dec 9; 6, Article number: 10001 doi:10.1038/ncomms10001 David TW Jones, Natalie Jäger, … Peter Lichter. ICGC PedBrain: Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 2; 488(7409): 100–105. doi:10.1038/nature11284 Jeremy Schwartzentruber, Andrey Korshunov, … Nada Jabado. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012 Feb 9; 482, 226–231 doi:10.1038/nature10833 Active Motif Contact Details Follow Active Motif on Twitter Follow our Epigenetics Podcast on Twitter Join us on LinkedIn Like us on Facebook Email us @Active Motif Europe or Active Motif North America.

Mia Dede doesn’t look like a typical warrior. This beautiful young girl with a huge smile and endearing shyness does not look like she was ever anything but happy. She was just two years old when her mother rushed her to the emergency room. It was Mother’s Day, and Cynthia Diaz should have been simply enjoying the day, but Mia “could barely stand still without falling” and Cynthia knew there was something seriously wrong with her daughter. Mia was diagnosed with Medulloblastoma a Brain tumor. She lived in a hospital for 7 months undergoing 6 cycles of high dose chemotherapy and finally recovered from the final stage in her treatment - a stem cell transplant. Today, Mia is a healthy 10 year-old girl that is lucky to never have had to spend another night in the hospital since treatment ended. Now, this young cancer survivor is making sure other kids like her find some brightness in their darkest days. If you enjoyed this episode, check out the featured article, video, and more at americansnippets.com/015

Prof Walker talks to ecancertv at Children with Cancer UK’s workshop on Drug Delivery in Paediatric Brain Tumours in London, UK. In the interview he discusses the use of intrathecal therapy in children with medulloblastoma. In particular he discusses the findings of a literature review looking at the range of drugs that may be suitable for intrathecal administration. The analysis found 126 candidate drugs of which only 12 were selected as eligible for further clinical investigation at this point. A further 15 were thought probably for further pre-clinical investigation.

Dr Singh speaks with ecancertv at NCRI 2016 about the pathways through which cancer stem cells drive tumourigenesis and subvert treatments, in the specific setting of medulloblastoma. She describes research with patient-derived xenograft models to modify treatment regimens, giving insight into opportunities to avoid the systemic toxicities associated with current therapies.

In this episode, we talked about: How they discovered her daughter’s brain cancer in October 2016.How quickly they acted between diagnosis to surgery (less than 24 hours).Medulloblastoma is the leading cause of childhood brain cancer.Her daughter’s tumor reoccurrence in different areas of her brain and spine just a few months after her treatment ended.The way her family has changed their norm for this summer to give Layla as much fun as possible!Money, insurance and starting a GoFundMe.The support of case workers and oncologists who advocate for your child alongside you.All of the stresses that families with medical hardship suffer in addition to the stress of hospital stays.Their current fundraiser, a golf tournament and the story behind it.Becoming a part of another foundation, Carson Leslie Foundation. 

Daniela Marazziti, BCN-CNR, Monterotondo, Italy speaks on "Mouse mutant models of cerebellum development and medulloblastoma". This movie has been recorded at ICGEB Trieste.

Michael Taylor discusses treatment approaches to the rare brain tumour that generally affects children, medulloblastoma.

Medulloblastoma is the commonest malignant brain tumour in childhood. This podcast describes the investigations and treatment of medulloblastoma.

June 09, 2011 An oncolytic virus for a common childhood brain tumor In this eighth episode of "This Week in Pediatric Oncology" podcast hosts Dr. Tim Cripe, Dr. Lars Wagner and Dr. Lionel Chow discuss a recent publication by researchers at Baylor/Texas Children's in Houston that shows remarkable results of Seneca Valley virus SVV-001 on orthotopic mouse models of medulloblastoma. The TWiPO hosts raise many interesting points about this research and highlight the strengths as well as limitations of this work. This exciting research provides new evidence of promise for oncolytic virus therapy for childhood tumors. For more information about oncolytic virus trials for pediatric cancers, see a recent webinar "Oncolytic Virotherapy for Pediatric Solid Tumors" presented by the principal investigators of five clinical trials in children and sponsored by Solving Kids' Cancer. The article discussed in this episode can be found here: A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Yu L, Baxter PA, et al. Neuro Oncol. 2011 Jan;13(1):14-27. Epub 2010 Nov 12. Another related article by the same group: Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus. Wadhwa L, Hurwitz MY, et al. Cancer Res. 2007 Nov 15;67(22):10653-6. [fulltext] Please send questions or comments to twipo@solvingkidscancer.org

Children treated for medulloblastoma using reduced dose craniospinal radiation with local tumor bed boost have improved neurocognitive outcomes compared with conventional therapy, pointing to an opportunity for prevention of severe late effects by treatment modification.

Thu, 24 Jan 2013 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/15294/ https://edoc.ub.uni-muenchen.de/15294/1/Frick_Alexandra.pdf Frick, Alexandra ddc:610, ddc:600,

Learning Objective: To review the current management and treatment of childhood medulloblastoma To understand the clinical implications of medulloblastoma from a patient's point of view To discuss recent evidence for the presence of a medulloblastoma stem cell that drives tumorigenesis in this malignant childhood tumor. To understand how developmental signaling pathways may be aberrantly activated to cause this childhood brain tumour.

Learning Objectives: To review the current management and treatment of childhood medulloblastoma To understand the clinical implications of medulloblastoma from a patient's point of view To discuss recent evidence for the presence of a medulloblastoma stem cell that drives tumorigenesis in this malignant childhood tumor. To understand how developmental signaling pathways may be aberrantly activated to cause this childhood brain tumour.

Das Medulloblastom ist der häufigste maligne Hirntumor des Kindesalters, und die Entwicklung von zielgerichteten, nebenwirkungsarmen Therapiestrategien hat oberste Priorität. Die molekularen Mechanismen der malignen Transformation dieses Tumors sind noch nicht bis ins Letzte verstanden, jedoch ist bekannt, dass Medulloblastome von Körnerzellvorläufern abstammen können. Barhl1 ist einer der Transkriptionsfaktoren, die das Überleben und die Migration von Körnerzellvorläufern steuern, jedoch ist die Funktion, die Barhl1 im Medulloblastom hat, noch unbekannt. Diese Arbeit zeigt, dass die Expression von BARHL1 während der Entwicklungsphase des menschlichen Kleinhirns und in humanen Medulloblastomen im Vergleich zu Kleinhirnen von Erwachsenen signifikant hochreguliert ist. Hohe Barhl1 Expressionslevel wurden zudem in Medulloblastomen von Math1-cre:SmoM2Fl/+ Mäusen gefunden, welche ein bewährtes Mausmodel für Sonic hedgehog-assoziierte Medulloblastome darstellen, die von cerebellären Körnerzellvorläufern abstammen. Um die Funktion von Barhl1 in vivo während der Entwicklung und des Wachstums von Medulloblastomen zu untersuchen, wurden Barhl1-/- Math1-cre:SmoM2Fl/+ und Barhl1+/-Math1-cre:SmoM2Fl/+ Mäuse generiert. Interessanterweise zeigten Tumoren, die in diesen Mäusen entstanden, eine vermehrte mitotische Aktivität und eine verminderte neuronale Differenzierung. Zudem war das Überleben dieser Mäuse im Vergleich zu dem von Math1-cre:SmoM2Fl/+ Mäusen signifikant verkürzt. Im Einklang mit diesen Ergebnissen zeigten Patienten, deren Medulloblastom eine niedrige BARHL1 Expression aufwies, eine schlechtere Prognose als Patienten, deren Tumoren eine höhere BARHL1 Expression aufwiesen. Diese Ergebnisse deuten darauf hin, dass die Expression von Barhl1 das Tumorwachstum in murinen und humanen Medulloblastomen verlangsamt. Deswegen sollte BARHL1 im Hinblick auf potentielle Anwendungen für individualisierte therapeutische Strategien weiter untersucht werden.

Fri, 05 Sep 2008 16:23:15 GMT https://www.screencast.com/users/RadOnc/folders/University+of+Alabama+at+Birmingham+Radiation+Oncology/media/1bf2fb04-e3bc-40a7-81ac-ec081f1c4eb5 https://www.screencast.com/users/RadOnc/folders/University+of+Alabama+at+B